End-of-day quote
Shenzhen S.E.
03:30:00 30/04/2024 am IST
|
5-day change
|
1st Jan Change
|
7.07
CNY
|
+1.14%
|
|
+3.06%
|
-20.65%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,900
|
2,207
|
2,204
|
2,992
|
2,681
|
2,949
|
Enterprise Value (EV)
1 |
2,302
|
2,437
|
2,335
|
3,087
|
2,721
|
2,835
|
P/E ratio
|
27.5
x
|
28.8
x
|
27.5
x
|
31.2
x
|
32.3
x
|
31.1
x
|
Yield
|
-
|
0.75%
|
0.45%
|
0.33%
|
0.62%
|
1.68%
|
Capitalization / Revenue
|
1.95
x
|
2.18
x
|
2.62
x
|
3.41
x
|
3.23
x
|
3.45
x
|
EV / Revenue
|
2.36
x
|
2.41
x
|
2.77
x
|
3.52
x
|
3.28
x
|
3.32
x
|
EV / EBITDA
|
15.9
x
|
16.2
x
|
17
x
|
20.1
x
|
21.2
x
|
21.2
x
|
EV / FCF
|
235
x
|
17.7
x
|
51.6
x
|
561
x
|
35.2
x
|
34
x
|
FCF Yield
|
0.43%
|
5.66%
|
1.94%
|
0.18%
|
2.84%
|
2.94%
|
Price to Book
|
1.02
x
|
1.14
x
|
1.1
x
|
1.44
x
|
1.24
x
|
1.32
x
|
Nbr of stocks (in thousands)
|
3,30,952
|
3,30,952
|
3,30,952
|
3,30,952
|
3,30,952
|
3,30,952
|
Reference price
2 |
5.740
|
6.670
|
6.660
|
9.040
|
8.100
|
8.910
|
Announcement Date
|
15/04/19
|
15/04/20
|
16/04/21
|
19/04/22
|
18/04/23
|
18/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
975.1
|
1,013
|
842.6
|
877.9
|
830
|
853.7
|
EBITDA
1 |
145.1
|
150.6
|
137.4
|
153.4
|
128.6
|
133.6
|
EBIT
1 |
105.7
|
109.1
|
97.4
|
114
|
88.73
|
88.53
|
Operating Margin
|
10.84%
|
10.77%
|
11.56%
|
12.98%
|
10.69%
|
10.37%
|
Earnings before Tax (EBT)
1 |
100.1
|
108.1
|
105
|
123.4
|
101.2
|
111.8
|
Net income
1 |
69.08
|
76.6
|
80.06
|
96.02
|
83.1
|
94.73
|
Net margin
|
7.08%
|
7.56%
|
9.5%
|
10.94%
|
10.01%
|
11.1%
|
EPS
2 |
0.2087
|
0.2314
|
0.2419
|
0.2901
|
0.2511
|
0.2862
|
Free Cash Flow
1 |
9.786
|
137.9
|
45.22
|
5.502
|
77.27
|
83.26
|
FCF margin
|
1%
|
13.61%
|
5.37%
|
0.63%
|
9.31%
|
9.75%
|
FCF Conversion (EBITDA)
|
6.75%
|
91.52%
|
32.92%
|
3.59%
|
60.1%
|
62.33%
|
FCF Conversion (Net income)
|
14.17%
|
179.98%
|
56.48%
|
5.73%
|
92.99%
|
87.89%
|
Dividend per Share
|
-
|
0.0500
|
0.0300
|
0.0300
|
0.0500
|
0.1500
|
Announcement Date
|
15/04/19
|
15/04/20
|
16/04/21
|
19/04/22
|
18/04/23
|
18/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
402
|
230
|
131
|
95.2
|
40.4
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
114
|
Leverage (Debt/EBITDA)
|
2.772
x
|
1.527
x
|
0.9534
x
|
0.6208
x
|
0.3145
x
|
-
|
Free Cash Flow
1 |
9.79
|
138
|
45.2
|
5.5
|
77.3
|
83.3
|
ROE (net income / shareholders' equity)
|
4.4%
|
4.59%
|
4.28%
|
4.84%
|
3.97%
|
4.2%
|
ROA (Net income/ Total Assets)
|
2.54%
|
2.7%
|
2.3%
|
2.52%
|
1.9%
|
1.84%
|
Assets
1 |
2,722
|
2,836
|
3,480
|
3,815
|
4,369
|
5,148
|
Book Value Per Share
2 |
5.610
|
5.840
|
6.030
|
6.290
|
6.510
|
6.750
|
Cash Flow per Share
2 |
0.1200
|
0.1900
|
0.8700
|
0.6600
|
1.040
|
1.470
|
Capex
1 |
73.7
|
21.7
|
75.9
|
107
|
41.4
|
35.8
|
Capex / Sales
|
7.56%
|
2.14%
|
9.01%
|
12.2%
|
4.98%
|
4.19%
|
Announcement Date
|
15/04/19
|
15/04/20
|
16/04/21
|
19/04/22
|
18/04/23
|
18/04/24
|
|
1st Jan change
|
Capi.
|
---|
| -20.65% | 323M | | +21.85% | 546B | | -4.77% | 359B | | +16.97% | 323B | | +5.69% | 290B | | +13.68% | 234B | | +3.65% | 198B | | -11.12% | 194B | | +8.08% | 167B | | -3.40% | 157B |
Other Pharmaceuticals
|